Perceptive Advisors - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Perceptive Advisors ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$37,583,389
+7.1%
1,263,732
-35.1%
1.25%
+23.5%
Q2 2023$35,083,805
-38.5%
1,946,937
-45.2%
1.02%
-39.8%
Q1 2023$57,091,485
-22.8%
3,554,887
-12.0%
1.69%
-18.8%
Q4 2022$73,918,751
-29.3%
4,039,276
-24.1%
2.08%
-31.6%
Q3 2022$104,505,000
+5.3%
5,321,0320.0%3.03%
-2.4%
Q2 2022$99,237,000
-12.4%
5,321,032
+3.1%
3.11%
+36.9%
Q1 2022$113,339,000
-61.4%
5,163,517
-50.0%
2.27%
+0.3%
Q4 2021$293,392,000
+251.7%
10,327,034
+160.6%
2.26%
+86.7%
Q3 2021$83,432,000
-44.2%
3,963,517
-50.0%
1.21%
+24.9%
Q2 2021$149,424,000
+189.5%
7,927,034
+116.6%
0.97%
+48.5%
Q1 2021$51,606,000
-0.1%
3,659,3810.0%0.65%
+17.9%
Q4 2020$51,634,000
-10.0%
3,659,3810.0%0.55%
-33.8%
Q3 2020$57,342,000
-3.1%
3,659,3810.0%0.84%
-12.7%
Q2 2020$59,171,000
+55.5%
3,659,381
+41.4%
0.96%
-3.2%
Q1 2020$38,042,000
-41.4%
2,587,9530.0%0.99%
-23.2%
Q4 2019$64,931,000
+66.8%
2,587,9530.0%1.29%
+23.0%
Q3 2019$38,922,000
-39.8%
2,587,9530.0%1.05%
-29.4%
Q2 2019$64,698,000
+9.8%
2,587,9530.0%1.48%
-10.6%
Q1 2019$58,901,000
-24.1%
2,587,9530.0%1.66%
-43.7%
Q4 2018$77,612,000
+4.7%
2,587,9530.0%2.95%
+49.0%
Q3 2018$74,144,0002,587,9531.98%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders